New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:02 EDTLJPCLa Jolla Pharmaceutical price target raised to $32 from $27 at Wedbush
Wedbush increased its price target on La Jolla after the company's GCS-100 drug facilitated statistically significant improvement in kidney function in CKD patients in a Phase 2a trial. The firm thinks the company will respond by taking the drug forward in CKD, and by activating clinical trials in multiple pipeline candidates. Wedbush keeps an Outperform rating on the stock.
News For LJPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LJPC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use